Investigational drug · Phase 2
PRGN-2009
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "PRGN-2009"
First trial start
2025
Nov 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PRGN-2009", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cervical Cancer
- HPV-Related Carcinoma
- HPV-Related Malignancy
- Recurrent Cervical Carcinoma
- Metastatic Cervical Cancer
Approved drugs for the same conditions: Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "PRGN-2009" as an intervention, largest first.
National Cancer Institute (NCI)NIH
NCT06223568 · 70 participants (planned) · Start Jun 10, 2024 · Primary completion Jan 10, 2028
Drug: Docetaxel; Cisplatin and 1 more · For: Squamous Cell Carcinoma of the Head and Neck; Oropharynx; Human Papillomavirus Viruses and 2 more
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT04432597 · 39 participants · Start Aug 11, 2020 · Primary completion Nov 22, 2022
Drug: PRGN-2009; M7824 · For: HPV Positive Cancer; Vulvar, Vaginal, Penile, Rectal Cancer; Anal Cancer and 2 more
Sites: Bethesda, Maryland
- Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal CancerActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05996523 · 26 participants · Start Nov 7, 2023 · Primary completion May 22, 2025
Drug: PRGN-2009; Pembrolizumab · For: Oropharyngeal Squamous Cell Carcinoma (SCC)
Sites: Bethesda, Maryland
- PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerRecruiting
Precigen, IncIndustry
NCT06157151 · 24 participants (planned) · Start Nov 11, 2025 · Primary completion Nov 11, 2026
Drug: PRGN-2009 plus Pembrolizumab · For: Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy and 2 more
Sites: Little Rock, Arkansas; Bethesda, Maryland; Seattle, Washington
Newest research
PubMed records naming it or its code names, newest first.
- PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer.
Floudas CS, Goswami M, Donahue RN, et al. · Cancer Immunol Immunother 2025
- Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009.
Pellom ST, Smalley Rumfield C, Morillon YM, et al. · JCI Insight 2021
Also in development for Cervical Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- SYS6002Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.